Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non - small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 8, 2011, Pages 1075-1082

  Rudin, Charles M ^a   Mauer, Ann ^a   Smakal, Martin ^a   Juergens, Rosalyn ^a   Spelda, Stanislav ^a   Wertheim, Michael ^a   Coates, Andrew ^a   McKeegan, Evelyn ^a   Ansell, Peter ^a   Zhou, Xiangdong ^a   Qian, Jane ^a   Pradhan, Rajendra ^a   Dowell, Barry ^a   Krivoshik, Andrew ^a   Gordon, Gary ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; CYTOKERATIN 19 FRAGMENT; FOLIC ACID; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PEMETREXED; PLACEBO; PLACENTAL GROWTH FACTOR; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; INSOMNIA; INTESTINE INFARCTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CZECH REPUBLIC; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79952764349     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5944     Document Type: Article

References (31)

1. ALIMTA (pemetrexed) package insert. Indianapolis, IN, Eli Lilly and Company
2. TAXOTERE (docetaxel) package insert. Bridgewater, NJ, sanofi-aventis
3. TARCEVA (erlotinib) package insert. Melville, NY, OSI Pharmaceuticals
4. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
5. Kubota K, Niho S, Enatsu S, et al: Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: Review of results from an open-label randomized phase II study. J Thorac Oncol 4:1530-1536, 2009
6. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 14:253-263, 2009
7. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
8. Cohen MH, Justice R, Pazdur R: Approval summary: Pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14:930-935, 2009
9. Yoshimatsu K, Yamaguchi A, Yoshino H, et al: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57:3208-3213, 1997 (Pubitemid 27351737)
10. Galmarini CM: ABT-751 (Abbott). Curr Opin Investig Drugs 6:623-630, 2005
11. Segreti JA, Polakowski JS, Koch KA, et al: Tumor selective antivascular effects of the novel antimitotic compound ABT-751: An in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54:273-281, 2004 (Pubitemid 39141745)
12. Koyanagi N, Nagasu T, Fujita F, et al: In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54:1702-1706, 1994
13. Jorgensen TJ, Tian H, Joseph IB, et al: Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 59:725-732, 2007 (Pubitemid 46440594)
14. Yamamoto K, Noda K, Yoshimura A, et al: Phase I study of E7010. Cancer Chemother Pharmacol 42:127-134, 1998 (Pubitemid 28267293)
15. Hande KR, Hagey A, Berlin J, et al: The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase I study. Clin Cancer Res 12:2834-2840, 2006
16. Mauer AM, Szeto L, Belt RJ, et al: Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC). J Clin Oncol 23:654s, 2005 (suppl; abstr 7137)
17. Mauer AM, Cohen EE, Ma PC, et al: A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 3:631-636, 2008 (Pubitemid 351787308)
18. Benson AB, Kindler HL, Jodrell D, et al: Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J Clin Oncol 23:255s, 2005 (suppl; abstr 3537)
19. Hagey AE, Figlin RA, Moldawer N, et al: Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). J Clin Oncol 23:403s, 2005 (suppl; abstr 4603)
20. Washington DK, Storniolo AV, Saleh M, et al: Phase 2 results of ABT-751 in subjects with taxanerefractory breast cancer: Interim analysis. J Clin Oncol 23:59s, 2005 (suppl; abstr 724)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Rudek MA, Zhao M, He P, et al: Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 42:253-260, 2006 (Pubitemid 44279332)
23. Haas M, Laubender RP, Stieber P, et al: Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 31:351-357, 2010
24. Holdenrieder S, von Pawel J, Dankelmann E, et al: Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 14:7813-7821, 2008
25. Molina R, Auge JM, Bosch X, et al: Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: Correlation with histology. Tumour Biol 30:121-129, 2009
26. Molina R, Filella X, Auge JM, et al: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24:209-218, 2003 (Pubitemid 37500571)
27. Ardizzoni A, Cafferata MA, Tiseo M, et al: Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 107:2842-2849, 2006 (Pubitemid 44937038)
28. OSI-774 Investigators Brochure. Boulder, CO, OSI Pharmaceuticals, 2001
29. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004 (Pubitemid 39095313)
30. Molina R, Auge JM, Filella X, et al: Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 25:1773-1778, 2005 (Pubitemid 40896801)
31. Zhang L, Chen J, Ke Y, et al: Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3:68, 2005